Pfizer’s quarterly profit beat market estimates, partly helped by higher-than-expected sales of its blockbuster pneumonia vaccine, Prevnar. The company also raised its full-year earnings forecast.

Pfizer posted basically flat first-quarter earnings, prompting suggestions the largest US drugmaker needs to do deals in order to improve its growth prospects.